ACERTIS PHARMS
SpecialtyACERTIS PHARMS is a specialty pharmaceutical company focused on Cardiovascular.
ACERTIS PHARMS's Key Drugs
ACERTIS PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ACERTIS PHARMS's Recent FDA Approvals
New NDA/BLA approvals for ACERTIS PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
ACERTIS PHARMS's Therapeutic Areas
ACERTIS PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ACERTIS PHARMS's Top Competitors
ACERTIS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ACERTIS PHARMS Pipeline Snapshot
Active clinical trials for ACERTIS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1977-08-19
- Latest
- 2026-06-18
- Applications
- 6